🇺🇸 FDA

Company profile · Sponsor

Viridian

Viridian Pharma Ltd

VRDN · NYSE pharma WALTHAM, MA, GB
Pipeline
13
Drugs
1
Patents
3

Quick answer

Viridian (VRDN) is a pharma company. headquartered in WALTHAM, MA, GB. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 1 drug, and 3 patents to this profile..

Company facts

Ticker VRDN
Exchange NYSE
Company type pharma
Headquarters WALTHAM, MA, GB
SEC CIK 0001590750

Pipeline (13)

Search pipeline →

  1. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  2. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor), VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian

    Thyroid eye disease (TED)

    phase 3 small molecule active

    1 trial

  3. Sodium Chloride 0.9% Intravenous Infusion, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  4. Ted sc placebo, VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension)

    Viridian

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  5. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  6. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  7. VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  8. VRDN-001 10 mg/kg

    Viridian

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  9. VRDN-001 Phase 3 Cohort (THRIVE)

    Viridian

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  10. VRDN-003

    Viridian

    Thyroid Eye Disease

    phase 3 small molecule active

    3 trials

  11. VRDN-003

    Viridian

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  12. Veligrotug

    Viridian

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  13. Veligrotug (VRDN-001)

    Viridian

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. caffeine citrate

    BLECTIFOR

    ORAL approved

    N06BC01

Patents (3)

Search patents →

  1. US 12404335

    Compositions and methods for treatment of thyroid eye disease

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12404337

    Compositions, doses, and methods for treatment of thyroid eye disease

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11548951

    Compositions and methods for treatment of thyroid eye disease

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Viridian?

Viridian (VRDN) is a pharma company. headquartered in WALTHAM, MA, GB. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 1 drug, and 3 patents to this profile..

What pipeline programs does Viridian sponsor?

We track 13 ClinicalTrials.gov-linked programs for Viridian, including SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor) and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Viridian company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.